Literature DB >> 3346076

Protective role of magnesium in the neutralization by antibodies of Chlamydia trachomatis infectivity.

E M Peterson1, G M Zhong, E Carlson, L M de la Maza.   

Abstract

Neutralization of the infectivity of Chlamydia trachomatis was assessed by using polyclonal antisera and monoclonal antibodies (MAbs). Polyclonal antisera and a species-reactive MAb as well as a subspecies-specific MAb, both of which were directed toward the major outer membrane protein of C. trachomatis, reduced the number of chlamydial inclusion-forming units in an in vitro assay. Neutralization was dependent on the presence of complement. The species-specific MAb reacted with all 15 serovars by a microimmunofluorescence assay and a dot blot enzyme-linked immunosorbent assay with heat-treated elementary bodies. On the other hand, this same MAb reacted with all serovars, except those in the C complex, by the dot blot enzyme-linked immunosorbent assay with viable organisms and neutralized in vitro all 10 serovars tested, except those in the C complex. When neutralization assays were performed in a solution containing Mg2+, neutralization by both polyclonal antisera and MAbs was significantly reduced. A dose response to Mg2+ supplied as MgSO4 revealed that all concentrations tested from 50 to 800 microM had some effect. Concentrations of greater than or equal to 400 microM MgSO4 completely abolished neutralization at the lowest dilution of polyclonal antisera and species-reactive MAb tested. Although Mg2+ also blocked the neutralization effect of the subspecies-specific MAb, this neutralization was not as complete as that observed with the species-reactive MAb. Addition of Mg2+ to the assay over the initial 45 min of incubation of C. trachomatis with MAb and complement showed that the organisms could be rescued to some extent over the first 30 min of incubation, after which time neutralization of infectivity could not be reversed. C. trachomatis treated with Mg2+, the species-reactive MAb, and complement were lethal to mice in an in vivo toxicity and infectivity assay, whereas mice injected with organisms incubated with the same MAb and complement without Mg2+ survived.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3346076      PMCID: PMC259385          DOI: 10.1128/iai.56.4.885-891.1988

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Neutralization of Chlamydia trachomatis in cell culture.

Authors:  L V Howard
Journal:  Infect Immun       Date:  1975-04       Impact factor: 3.441

2.  Sensitization of complement-resistant smooth gram-negative bacterial strains.

Authors:  B L Reynolds; H Pruul
Journal:  Infect Immun       Date:  1971-03       Impact factor: 3.441

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  A simplified ultrasensitive silver stain for detecting proteins in polyacrylamide gels.

Authors:  B R Oakley; D R Kirsch; N R Morris
Journal:  Anal Biochem       Date:  1980-07-01       Impact factor: 3.365

5.  The genus-specific antigen of Chlamydia: resemblance to the lipopolysaccharide of enteric bacteria.

Authors:  M Nurminen; M Leinonen; P Saikku; P H Mäkelä
Journal:  Science       Date:  1983-06-17       Impact factor: 47.728

Review 6.  Genital infections.

Authors:  L M de la Maza; E M Peterson
Journal:  Med Clin North Am       Date:  1983-09       Impact factor: 5.456

7.  Neutralization of Chlamydia trachomatis cell culture infection by serovar-specific monoclonal antibodies.

Authors:  M E Lucero; C C Kuo
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

8.  Antigenic properties of Chlamydia trachomatis lipopolysaccharide.

Authors:  L Brade; M Nurminen; P H Mäkelä; H Brade
Journal:  Infect Immun       Date:  1985-05       Impact factor: 3.441

9.  Protective monoclonal antibodies recognize epitopes located on the major outer membrane protein of Chlamydia trachomatis.

Authors:  Y X Zhang; S Stewart; T Joseph; H R Taylor; H D Caldwell
Journal:  J Immunol       Date:  1987-01-15       Impact factor: 5.422

10.  Serum-resistant mutants of Escherichia coli O111 contain increased lipopolysaccharide, lack an O antigen-containing capsule, and cover more of their lipid A core with O antigen.

Authors:  R C Goldman; K Joiner; L Leive
Journal:  J Bacteriol       Date:  1984-09       Impact factor: 3.490

View more
  51 in total

1.  Inclusion fluorescent-antibody test as a screening assay for detection of antibodies to Chlamydia pneumoniae.

Authors:  Olga Tapia; Anatoly Slepenkin; Evgueni Sevrioukov; Kathi Hamor; Luis M de la Maza; Ellena M Peterson
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

2.  Immunization with a peptide corresponding to chlamydial heat shock protein 60 increases the humoral immune response in C3H mice to a peptide representing variable domain 4 of the major outer membrane protein of Chlamydia trachomatis.

Authors:  V L Motin; L M de la Maza; E M Peterson
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  Protection of mice from a Chlamydia trachomatis vaginal infection using a Salicylidene acylhydrazide, a potential microbicide.

Authors:  Anatoly Slepenkin; Hencelyn Chu; Mikael Elofsson; Pia Keyser; Ellena M Peterson
Journal:  J Infect Dis       Date:  2011-09-20       Impact factor: 5.226

Review 4.  Interaction of chlamydiae and host cells in vitro.

Authors:  J W Moulder
Journal:  Microbiol Rev       Date:  1991-03

5.  Antigenic determinants of the chlamydial major outer membrane protein resolved at a single amino acid level.

Authors:  G M Zhong; R C Brunham
Journal:  Infect Immun       Date:  1991-03       Impact factor: 3.441

6.  Increased immunoaccessibility of MOMP epitopes in a vaccine formulated with amphipols may account for the very robust protection elicited against a vaginal challenge with Chlamydia muridarum.

Authors:  Delia F Tifrea; Sukumar Pal; Jean-Luc Popot; Melanie J Cocco; Luis M de la Maza
Journal:  J Immunol       Date:  2014-04-28       Impact factor: 5.422

7.  Characterization of a neutralizing monoclonal antibody directed at variable domain I of the major outer membrane protein of Chlamydia trachomatis C-complex serovars.

Authors:  Z Qu; X Cheng; L M de la Maza; E M Peterson
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

8.  Protection against infertility in a BALB/c mouse salpingitis model by intranasal immunization with the mouse pneumonitis biovar of Chlamydia trachomatis.

Authors:  S Pal; T J Fielder; E M Peterson; L M de la Maza
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

9.  Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron.

Authors:  Anatoly Slepenkin; Per-Anders Enquist; Ulrik Hägglund; Luis M de la Maza; Mikael Elofsson; Ellena M Peterson
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

10.  The cell-penetrating peptide, Pep-1, has activity against intracellular chlamydial growth but not extracellular forms of Chlamydia trachomatis.

Authors:  Narae Park; Kinrin Yamanaka; Dat Tran; Pete Chandrangsu; Johnny C Akers; Jessica C de Leon; Naomi S Morrissette; Michael E Selsted; Ming Tan
Journal:  J Antimicrob Chemother       Date:  2008-10-27       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.